Cargando…

RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases

Inflammatory bowel diseases (IBDs) are becoming more frequent worldwide. A significant fraction of patients with IBD are refractory to various types of therapeutic biologics and small molecules. Therefore, identification of novel therapeutic targets in IBD is required. Receptor-interacting serine/th...

Descripción completa

Detalles Bibliográficos
Autores principales: Honjo, Hajime, Watanabe, Tomohiro, Kamata, Ken, Minaga, Kosuke, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079979/
https://www.ncbi.nlm.nih.gov/pubmed/33935757
http://dx.doi.org/10.3389/fphar.2021.650403